央广网北京12月11日消息（总台记者管昕 谢元森 钱成）据中央广播电视总台中国之声《新闻纵 横》报道，这两天，"水银体温计血压计明年起禁产"的话题冲上热搜。根据国家药监局通知，自2026年 1月1号起，我国将全面禁止生产含汞体温计和含汞血压计产品。 水银体温计进入停产倒计时，多家医疗器械生产企业表示，近期水银体温计货源处于供不应求状 态。水银体温计向来以"便宜又准确"深受大众青睐，为何要全面禁产？市面上有哪些靠谱的替代产品？ 记者昨天（12月10日）在江西省南昌市走访了多家药店，均被告知水银体温计已售罄。 记者：水银的体温计还有吗？ 店员：现在没货。今天有人一次性就买了5根，现在没有了。 店员表示，这几天水银体温计销量略有上涨，但价格和此前没有变化。 生产商：订不到了。我们现在根据计划在减产了，要逐步地停产，到12月30号就停了，产能有限。 看似"便宜又好用"的老式水银体温计为何要禁产？据了解，汞具有剧毒性，还会造成环境污染。根 据原环境保护部会同相关部委2017年发布的第38号公告，《关于汞的水俣公约》自2017年8月16日起对 我国生效，其中明确"自2026年1月1日起，禁止生产含汞体温计和含汞血压计。" ...

Group 1 - The report indicates a continued decline in risk appetite, with the short-term trading indicators for the North Exchange reaching absolute lows. The North Exchange 50 index fell by 4.91%, which is less than the declines of the Sci-Tech 50 (-6.16%) and the ChiNext index (-5.71%) [7][12][13] - The market's risk appetite has significantly decreased, with major indices declining and trading volume shrinking. The banking and coal sectors showed strength, while TMT, robotics, and solid-state battery sectors experienced notable declines, with only AI computing leaders performing stably [7][12] - The report anticipates increased market volatility due to several significant events occurring in late October, including the release of third-quarter economic data, quarterly reports from listed companies, and key policy meetings [7][8] Group 2 - This week, one new stock, Changjiang Nengke, was listed on the North Exchange, with a first-day price increase of 254.03%. As of October 17, 2025, there are 279 companies listed on the North Exchange [22][24] - The North Exchange's trading volume for the week was 3.958 billion shares, with a total transaction amount of 92.582 billion yuan. The average daily transaction amount decreased by 2.57% [12][18] - The report highlights that 34 stocks rose while 244 stocks fell, resulting in a rise-fall ratio of 0.14. The top gainers included Litong Technology and Wantong Hydraulic, while the top losers included Aomeisen and Luchao Information [29][30] Group 3 - The report notes that the North Exchange's PE (TTM) average is 77.79 times, with a median of 45.06 times, indicating a decline in valuation metrics [19][20] - The report emphasizes the importance of monitoring companies with marginal changes and suggests maintaining focus on core assets within the North Exchange [7][8] Group 4 - The new third board saw 10 new listings and 1 delisting this week, with planned financing of 453 million yuan and completed financing of 166 million yuan [39][40] - The report provides insights into the financing activities of companies on the new third board, highlighting significant fundraising efforts by companies like Ziguang Guoxin [41][42]

Core Viewpoint - Home blood pressure monitoring is a crucial aspect of hypertension management, providing accurate data for health management and disease prevention [1] Group 1: Choosing the Right Blood Pressure Monitor - Recommended to use upper arm electronic blood pressure monitors for their accuracy and ease of use, while wrist, finger monitors, and mercury sphygmomanometers are not recommended [2] - Ensure the blood pressure monitor is certified and calibrated regularly, ideally once a year [2] Group 2: Measurement Methodology - Preparation involves selecting a quiet room with a comfortable temperature, resting for at least 5 minutes before measurement, and emptying the bladder to avoid elevated readings [3] - Correct posture is essential, with the arm at heart level and the cuff positioned appropriately [4] Group 3: Measurement Process - The first measurement should be taken quietly, followed by a second measurement after 1-2 minutes, averaging the two readings. If there is a significant difference, a third measurement is recommended [5] - It is important to record the date, time, and blood pressure readings for long-term tracking [5] Group 4: Important Considerations - Awareness of the "white coat effect," where anxiety in clinical settings may lead to higher readings, is important, and excessive focus on blood pressure can cause anxiety [6] - Certain medications may affect blood pressure readings, and special populations like pregnant women or children should follow specific medical guidance [7] Group 5: Monitoring Frequency and Timing - Blood pressure should be measured at specific times: within one hour of waking and before breakfast, and after dinner before bedtime [9] - Frequency varies by blood pressure status, with normal individuals measuring at least once a year, while those with elevated readings should measure more frequently [11]

Regulatory Developments - The National Medical Products Administration reported four cases of illegal online sales of medical devices, emphasizing a "zero tolerance" regulatory attitude to ensure safety in medical device usage [2] - Companies involved include Jiangyin Tianyu Medical Device Co., Yiwu Shenghe Medical Device Co., Shanghai Yile Warehouse Medical Device Co., and Hefei Baohua Design Studio, all of which failed to comply with regulatory requirements [2] Industry Advancements - Hangzhou is accelerating the development of medical artificial intelligence applications, aiming to establish a national AI (medical) application pilot base and create intelligent medical entities focused on various health management areas [3] - The city plans to build digital health innovation laboratories to advance key technologies in medical AI [3] Company Announcements - Leksin Medical received a medical device registration certificate for its wrist-type electronic blood pressure monitor from the Guangdong Provincial Drug Administration [5] - David Medical's wholly-owned subsidiary, Ningbo Yongxing Medical Instruments Co., obtained a medical device registration certificate for a linear cutting stapler used in various surgical procedures [6] - Warner Pharmaceuticals announced the approval of its drug registration certificate for the injection of methoxamine hydrochloride, used for treating acute hypotension during spinal anesthesia [7] Financial Reports - Guobang Pharmaceutical reported a revenue of 1.44 billion yuan for Q1 2025, a year-on-year increase of 7.57%, with a net profit of 215 million yuan, up 8.17% [9] - Johnson & Johnson's Q1 sales reached 21.89 billion dollars, with an annual sales forecast of 91 to 91.8 billion dollars and adjusted earnings per share projected between 10.50 and 10.70 dollars [10] Market Movements - In Hong Kong, InnoCare's stock surged by 130% on its first trading day [12] - Darentang announced plans to transfer a 12% stake in China-US Tianjin Schering Pharmaceutical Co., with estimated investment income of approximately 1.54 billion yuan from the transaction [13] - Nanjing Noling Biotechnology completed a C-round financing of several hundred million yuan, led by Dingxin Capital [14] Collaborative Initiatives - Berry Genomics' subsidiary signed a project cooperation framework agreement with Beijing Children's Hospital to promote clinical transformation and commercialization of research outcomes related to newborn screening technologies [16] - Bangyan Technology plans to officially launch its AI Agent product this year, aimed at assisting digital transformation in the healthcare sector [17] Personnel Changes - Bell Bio's financial officer, Zhao Baozhen, resigned for personal reasons but will continue to serve as the board secretary [19]